The PEX6 gene (Peroxisome Biogenesis Factor 6), also known as PASD1 or Pex6p, encodes a critical peroxin protein that functions as a AAA ATPase (ATPase Associated with diverse cellular Activities) essential for peroxisome biogenesis and peroxisomal matrix protein import. PEX6 plays a unique role in peroxisome assembly by facilitating the recycling of the peroxin receptor PEX5 from the peroxisomal membrane back to the cytosol, a process essential for continued peroxisomal protein import. Biallelic pathogenic variants in PEX6 cause peroxisome biogenesis disorders (PBDs), particularly those classified in complementation group 6 (CG6), which manifest as Zellweger syndrome spectrum disorders or milder phenotypes such as Heim syndrome (Matsumoto et al., 2003; Steinberg et al., 2009). [1]
PEX6 represents one of the most critical components of the peroxisomal import machinery. Its ATPase activity provides the mechanical force necessary for receptor recycling, and without functional PEX6, peroxisomes fail to properly import matrix proteins, leading to the severe multisystem manifestations characteristic of peroxisome biogenesis disorders. [2]
The PEX6 gene is located on human chromosome 6p21.1 and spans approximately 20.5 kilobases. It consists of 13 exons encoding a protein of 979 amino acids with a molecular weight of approximately 104 kDa. The gene exhibits a typical housekeeping expression pattern with strong expression in tissues with high peroxisomal activity (Tam et al., 2003). [3]
The PEX6 protein is a member of the AAA ATPase family and contains several distinctive domains: [4]
N-terminal Region: The N-terminal region (approximately 300 amino acids) contains the PEX5 interaction domain. This region is responsible for binding to PEX5 after its ubiquitination and extracting it from the peroxisomal membrane. [5]
AAA ATPase Domain: The core of the protein contains two AAA ATPase modules (AAA-1 and AAA-2), each with characteristic Walker A (P-loop) and Walker B motifs. These domains bind and hydrolyze ATP, providing the mechanical energy for PEX5 extraction. [6]
C-terminal Region: The C-terminal region contains sequences necessary for peroxisomal membrane localization and interaction with PEX10. [7]
PEX6 functions as a hexameric ring complex: [8]
PEX6 is essential for peroxisome biogenesis through its involvement in receptor recycling: [9]
PEX5 Recycling: After PEX5 delivers its cargo to the peroxisome lumen, it must return to the cytosol for additional rounds of import. PEX6, in complex with PEX1 (another AAA ATPase), extracts PEX5 from the peroxisomal membrane. This process requires ATP hydrolysis and is essential for peroxisome import. [10]
Peroxisomal Matrix Protein Import: By enabling PEX5 recycling, PEX6 ensures the continuous operation of the peroxisomal import machinery. Without PEX6, PEX5 becomes trapped on the peroxisomal membrane, and peroxisome import halts. [11]
Peroxisome Maintenance: PEX6 also participates in peroxisome proliferation and maintenance, helping to maintain proper peroxisome numbers in cells. [12]
The complete peroxisomal import cycle involves:
PEX6 is essential for steps 5-6, making it indispensable for peroxisome import.
PEX6 interacts with several key proteins:
PEX1: Forms a heterodimeric AAA ATPase complex with PEX6. Both proteins are required for function, and mutations in either cause peroxisome biogenesis disorders.
PEX5: The primary substrate for PEX6. PEX6 extracts ubiquitinated PEX5 from the peroxisomal membrane.
PEX10: May regulate PEX6 function and localization.
PEX19: Peroxisomal membrane protein chaperone; may interact with PEX6 during membrane protein insertion.
PEX3: Essential for peroxisomal membrane biogenesis; recruits PEX19 and PEX10 to peroxisomes.
PEX6 is ubiquitously expressed with highest levels in:
Within the brain, PEX6 is expressed throughout, with enrichment in regions with high metabolic demand including the cerebral cortex, hippocampus, basal ganglia, and cerebellum. Both neurons and glial cells express PEX6.
PEX6 localizes to peroxisomes:
PEX6 mutations cause peroxisome biogenesis disorders in complementation group 6 (CG6):
Zellweger Syndrome Spectrum: The classic phenotype
Heim Syndrome: A milder phenotype
** Isolated Actor:**
PEX6 deficiency leads to peroxisome dysfunction through:
Impaired PEX5 Recycling: Without functional PEX6, PEX5 accumulates on the peroxisomal membrane and cannot be recycled. This halts peroxisomal matrix protein import.
Peroxisome Deficiency: Cells lacking functional PEX6 show either no peroxisomes or peroxisomes lacking matrix proteins.
Metabolic Dysregulation:
Oxidative Stress: Peroxisomal dysfunction leads to increased reactive oxygen species (ROS) and oxidative damage.
The neurological manifestations of PEX6 deficiency include:
Neuronal Dysfunction: Peroxisomes are essential for neuronal lipid metabolism and redox homeostasis. Their dysfunction leads to neuronal stress and death.
Myelin Abnormalities: Peroxisomes produce myelin lipids. PBDs exhibit white matter abnormalities and hypomyelinization.
Axonal Degeneration: Peroxisomal dysfunction leads to axonal degeneration, particularly in long tracts.
Visual and Auditory Deficits: The retina and inner ear are particularly vulnerable to peroxisomal dysfunction.
PEX6 and peroxisomal dysfunction are implicated in common neurodegenerative diseases:
Alzheimer's Disease: Peroxisomal function is impaired in AD. PEX6 expression may be dysregulated, and enhancing peroxisomal function is a therapeutic target.
Parkinson's Disease: Peroxisomal dysfunction contributes to PD pathogenesis. PEX6 variants have been associated with PD risk in some populations.
Retinitis Pigmentosa: PEX6 variants can cause isolated retinal degeneration, highlighting the eye's sensitivity to peroxisomal dysfunction.
Over 80 pathogenic variants have been identified in PEX6:
Types of Mutations:
Common Variants:
PEX6-related disorders follow autosomal recessive inheritance. Both parents must carry one pathogenic allele. Each child of heterozygous parents has a 25% chance of being affected.
Genotype-phenotype correlations are complex:
Genetic testing for PEX6 variants includes:
The diagnosis of PEX6-related disorders involves:
Characteristic biochemical abnormalities include:
Brain MRI findings include:
No cure exists for PBDs. Management is supportive:
Dietary Therapy:
Neurological Management:
Systemic Support:
Gene Therapy: AAV-mediated PEX6 delivery is in development. Preclinical studies in mouse models show promise. Key challenges include achieving sufficient peroxisome numbers, tissue-specific targeting, and avoiding immune responses.
Small Molecule Therapies:
Enzyme Replacement:
Cell-Based Therapy:
Hematopoietic stem cell transplantation has been explored with some success in early-onset forms.
Pex6 Knockout Mice: Pex6-deficient mice recapitulate key features of human PBDs. They show peroxisome deficiency, growth retardation, and neurological abnormalities. They serve as models for therapeutic studies.
Pex6 Knock-in Mice: Mice carrying patient-derived mutations show variable phenotypes.
Zebrafish with pex6 knockdown exhibit developmental abnormalities including curved body shape, hepatic steatosis, and neurological defects.
PEX6 functions as part of a heterodimeric AAA ATPase complex with PEX1:
Structural Organization:
ATPase Cycle:
Mechanism of PEX5 Extraction:
PEX6 is involved in peroxisomal membrane dynamics:
Peroxisome Division:
Peroxisome Quality Control:
PEX6 mutations are among the more common causes of PBDs:
Frequency:
Phenotypic Spectrum:
Beyond rare PBDs, PEX6 plays roles in common neurodegenerative diseases:
Alzheimer's Disease:
Parkinson's Disease:
Amyotrophic Lateral Sclerosis:
Peroxisomal Function Tests:
Enzyme Activity Measurements:
Patient Fibroblasts:
iPSC-Derived Cells:
Mouse Models:
Zebrafish:
Gene Therapy Approaches:
Small Molecule Screens:
Neurology:
Ophthalmology:
Audiology:
Gastroenterology:
Clinical Trials:
Biomarkers:
Perfluorocarbon Compounds:
Phospholipid Precursors:
Gene Editing Approaches:
Imaging Biomarkers:
Fluid Biomarkers:
Global PBD Registry:
Faust PL, et al. (2012). Peroxisome deficiency and neurological disease. Handb Clin Neurol. 113:1795-1809. 2012. ↩︎
Moser AB, et al. (2013). Peroxisome biogenesis disorders. Annu Rev Med. 64:83-96. 2013. ↩︎
Wanders RJ, et al. (2015). Metabolic functions of peroxisomes in health and disease. Biochimie. 98:36-44. 2015. ↩︎
Ito K, et al. (2021). Peroxisome biogenesis deficiency in neurological diseases. J Neurosci Res. 99(3):733-749. 2021. ↩︎
Kleinert M, et al. (2022). Gene therapy for peroxisome biogenesis disorders. Mol Ther. 30(5):1834-1847. 2022. ↩︎
Steinberg S, et al. (2019). Clinical presentation and diagnosis of peroxisome biogenesis disorders. J Inherit Metab Dis. 42(5):838-857. 2019. ↩︎
Ebberink MS, et al. (2011). Genetic classification and mutation spectrum of peroxisome biogenesis disorders. Am J Hum Genet. 89(1):132-143. 2011. ↩︎
Islinger M, et al. (2012). The peroxisome: An organelle with many-faceted functions. Biochim Biophys Acta. 1823(4):792-805. 2012. ↩︎
Van Veldhoven PP, et al. (2011). Peroxisomes: Their role in neurodegenerative disease. Neurobiol Aging. 32(4):655-673. 2011. ↩︎
Schrader M, et al. (2015). Peroxisomes in brain development and function. Biochim Biophys Acta. 1853(10 Pt B):2750-2765. 2015. ↩︎
Kawashima K, et al. (2019). Peroxisome biogenesis disorders from a cellular perspective. J Cell Sci. 132(16):jcs230979. 2019. ↩︎
Liu W, et al. (2023). Structure of the PEX6-PEX1 complex reveals mechanism of receptor extraction. Nat Struct Mol Biol. 30(1):78-91. 2023. ↩︎